With promising data from a Phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), Sanofi has begun a rolling Biologics License Application (BLA) for cemiplimab, a PD-1 inhibitor that is one of two clinical candidates it is counting on to make a competitive play in immuno-oncology.
Cemiplimab is part of the French pharma's 2015 IO partnership with long-time collaborator Regeneron Pharmaceuticals Inc.[See Deal]...






